SEQUENT Panoramica delle azioni Sequent Scientific Limited opera nel settore della sanità veterinaria in Europa, Asia e a livello internazionale. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Sequent Scientific Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Sequent Scientific Prezzi storici delle azioni Prezzo attuale dell'azione ₹181.48 Massimo di 52 settimane ₹240.70 Minimo di 52 settimane ₹92.05 Beta 0.81 Variazione di 1 mese 2.42% Variazione a 3 mesi 1.03% Variazione di 1 anno 31.13% Variazione a 3 anni 11.75% Variazione a 5 anni 114.01% Variazione dall'IPO 1.16%
Notizie e aggiornamenti recenti
Sequent Scientific Limited Announces Executive Changes Dec 19
Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024) Nov 14
Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024 Nov 07
Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director Oct 28 Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million Sep 28
Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion. Sep 27
Vedi altri aggiornamenti
Sequent Scientific Limited Announces Executive Changes Dec 19
Second quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.34 loss in 2Q 2024) Nov 14
Sequent Scientific Limited to Report Q2, 2025 Results on Nov 13, 2024 Nov 07
Sequent Scientific Limited Announces Cessation of Kausalya Santhanam as Independent Director Oct 28 Sequent Scientific and Viyash Life Sciences Reportedly Explore Merger Worth INR 70,000 Million-INR 80,000 Million Sep 28
Sequent Scientific Limited (BSE:512529) agreed to acquire Viyash Life Sciences Private Limited for INR 38 billion. Sep 27
We Think Sequent Scientific (NSE:SEQUENT) Is Taking Some Risk With Its Debt Sep 27
What Sequent Scientific Limited's (NSE:SEQUENT) 32% Share Price Gain Is Not Telling You Sep 05
Sequent Scientific Limited, Annual General Meeting, Sep 17, 2024 Aug 27
Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API Aug 21
New minor risk - Share price stability Aug 19
First quarter 2025 earnings released: EPS: ₹0.26 (vs ₹1.40 loss in 1Q 2024) Aug 16
Sequent Scientific Limited to Report Q1, 2025 Results on Aug 14, 2024 Aug 09
Full year 2024 earnings released: ₹1.44 loss per share (vs ₹4.88 loss in FY 2023) May 16
Sequent Scientific Limited to Report Q4, 2024 Results on May 15, 2024 May 10
Revenues Not Telling The Story For Sequent Scientific Limited (NSE:SEQUENT) Apr 05
Sequent Scientific Limited Announces Resignation of Sharat Pandurang Narasapur, Jt. Managing Director, from the Board of Directors, Member of the Corporate Social Responsibility Committee of the Board Effective on April 30, 2024 Apr 04
Third quarter 2024 earnings released: EPS: ₹0.33 (vs ₹0.36 loss in 3Q 2023) Feb 14
Sequent Scientific Limited Announces Executive Changes Feb 13
Sequent Scientific Limited to Report Q3, 2024 Results on Feb 13, 2024 Feb 07
Sequent Scientific Limited Announces Resignation of Krunal Shah as Company Secretary & Compliance Officer, Effective on February 15, 2024 Dec 06
Sequent Scientific Limited to Report Q2, 2024 Results on Nov 06, 2023 Oct 31
Sequent Scientific Limited Announces Patri Venkat Raghavendra Rao as Chief Financial Officer Oct 17
Sequent Scientific Limited, Annual General Meeting, Aug 30, 2023 Aug 09
Sequent Scientific Limited to Report Q1, 2024 Results on Aug 10, 2023 Aug 05
Sequent Scientific Limited Announces Discontinuation of Manufacturing Operations At Tarapur, Maharashtra Jul 15
Full year 2023 earnings released: ₹4.88 loss per share (vs ₹1.67 profit in FY 2022) May 24
Sequent Scientific (NSE:SEQUENT) Has A Somewhat Strained Balance Sheet Mar 10
Third quarter 2023 earnings released: ₹0.36 loss per share (vs ₹0.69 profit in 3Q 2022) Feb 15
Sequent Scientific Limited Announces Resignation of Rahul Mukim as Director Dec 08
Price target decreased to ₹149 Nov 16
High number of new and inexperienced directors Nov 16
Second quarter 2023 earnings released: ₹0.15 loss per share (vs ₹0.58 profit in 2Q 2022) Nov 09
Sequent Scientific Limited (BSE:512529) agreed to acquire Tineta Pharma Private Limited from group of shareholders for INR 2.18 billion. Nov 08 Sequent Scientific Limited to Report Q2, 2023 Results on Nov 14, 2022
Sequent Scientific Limited, Annual General Meeting, Sep 20, 2022 Aug 27
First quarter 2023 earnings released: ₹0.57 loss per share (vs ₹0.04 profit in 1Q 2022) Aug 10
Sequent Scientific Limited to Report Q1, 2023 Results on Aug 08, 2022 Aug 03
Investor sentiment improved over the past week Jul 20
Sequent Scientific Limited Appoints P V Raghavendra Rao as the Chief Financial Officer Jul 16
Investor sentiment deteriorated over the past week Jun 20
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind May 27
Investor sentiment improved over the past week May 23
Sequent Scientific Limited to Report Q4, 2022 Results on May 25, 2022 May 20
Price target decreased to ₹170 Apr 27
High number of new and inexperienced directors Apr 27
Sequent Scientific Limited Announces Resignation of Tushar Mistry Chief Financial Officer, Effective May 31, 2022 Apr 15 Sequent Scientific Limited Announces Resignation of Mr. Manish Gupta from the Position of CEO Sequent Scientific Limited Announces Appointment of Rajaram Narayanan as Managing Director
CEO, MD & Executive Director recently sold ₹73m worth of stock Apr 06
Investor sentiment improved over the past week Apr 04
CEO, MD & Executive Director recently sold ₹84m worth of stock Mar 28
CEO, MD & Executive Director recently sold ₹23m worth of stock Mar 06
CEO, MD & Executive Director recently sold ₹27m worth of stock Feb 23
Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 13
Price target decreased to ₹197 Jan 25
Insider recently sold ₹5.7m worth of stock Jan 05
Investor sentiment deteriorated over the past week Nov 30
Insider recently bought ₹1.4m worth of stock Nov 13
Second quarter 2022 earnings released: EPS ₹0.58 (vs ₹0.86 in 2Q 2021) Nov 04
Investor sentiment deteriorated over the past week Oct 22
Insider recently sold ₹17m worth of stock Sep 09
Insider recently sold ₹17m worth of stock Aug 27
Full year 2021 earnings released: EPS ₹3.87 (vs ₹2.87 in FY 2020) Jul 03
Insider recently sold ₹1.3m worth of stock Feb 21
Third quarter 2021 earnings released: EPS ₹1.54 (vs ₹0.83 in 3Q 2020) Feb 04
New 90-day high: ₹232 Feb 03
Is Sequent Scientific's (NSE:SEQUENT) 177% Share Price Increase Well Justified? Jan 31
Sequent Scientific Limited to Report Q3, 2021 Results on Feb 03, 2021 Jan 26
New 90-day high: ₹215 Jan 19
Investor sentiment improved over the past week Jan 19
How Much Did Sequent Scientific's (NSE:SEQUENT) CEO Pocket Last Year? Jan 17
Sequent Scientific Limited's (NSE:SEQUENT) Stock Is Going Strong: Have Financials A Role To Play? Jan 05
New 90-day high: ₹181 Jan 04
What Kind Of Investors Own Most Of Sequent Scientific Limited (NSE:SEQUENT)? Dec 24
Chief Financial Officer recently sold ₹7.7m worth of stock Dec 22
Sequent Scientific Limited Appoints Fabian Kausche as an Additional (Non-Executive Non-Independent) Director Dec 16
Have Sequent Scientific Limited (NSE:SEQUENT) Insiders Been Selling Their Stock? Dec 12
Insider recently sold ₹8.7m worth of stock Dec 10
New 90-day high: ₹169 Dec 07
Sequent Scientific Limited Announces Launch of Inhouse Developed Halofusol® in EU Dec 03
Insider recently sold ₹79m worth of stock Nov 25
Sequent Scientific (NSE:SEQUENT) Seems To Use Debt Rather Sparingly Nov 22
Insider recently sold ₹3.8m worth of stock Nov 14
Estimating The Intrinsic Value Of Sequent Scientific Limited (NSE:SEQUENT) Nov 10
Second quarter 2021 earnings released: EPS ₹0.86 Nov 08
Sequent Scientific Limited Appoints Gregory John Andrews as an Additional Director with Effect from November 6, 2020 Nov 07
Sequent Scientific Limited to Report Q2, 2021 Results on Nov 06, 2020 Nov 01
The Sequent Scientific (NSE:SEQUENT) Share Price Is Up 102% And Shareholders Are Boasting About It Oct 20
How Does Sequent Scientific's (NSE:SEQUENT) CEO Pay Compare With Company Performance? Oct 05
Insider recently sold ₹77m worth of stock Oct 03
New 90-day high: ₹159 Sep 29 Rendimenti per gli azionisti SEQUENT IN Pharmaceuticals IN Mercato 7D 6.4% -1.8% -0.3% 1Y 31.1% 26.8% 10.6%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: SEQUENT ha superato il Indian Pharmaceuticals che ha restituito 26.8 % nell'ultimo anno.
Rendimento vs Mercato: SEQUENT ha superato il mercato Indian che ha restituito 10.6 % nell'ultimo anno.
Volatilità dei prezzi Is SEQUENT's price volatile compared to industry and market? SEQUENT volatility SEQUENT Average Weekly Movement 7.0% Pharmaceuticals Industry Average Movement 6.0% Market Average Movement 6.3% 10% most volatile stocks in IN Market 9.1% 10% least volatile stocks in IN Market 4.2%
Prezzo delle azioni stabile: SEQUENT non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 7% ) di SEQUENT è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 1985 1,195 Rajaram Narayanan www.sequent.in
Sequent Scientific Limited opera nel settore della sanità veterinaria in Europa, Asia e a livello internazionale. L'azienda fornisce formulazioni di ingredienti farmaceutici attivi (API) per la salute degli animali nei settori degli antielmintici, compresi gli endo ed ecto parassiticidi, degli antiprotozoari, dei nutraceutici, degli antinfiammatori non steroidei, degli antinfettivi e della dermatologia. Offre inoltre soluzioni analitiche a supporto delle organizzazioni di API, farmaceutiche, di cura della persona e nutraceutiche, nonché convalida di metodi, stabilità e microbiologia per API e prodotti finiti.
Mostra di più Sequent Scientific Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Sequent Scientific con la sua capitalizzazione di mercato? SEQUENT statistiche fondamentali Capitalizzazione di mercato ₹43.28b Guadagni(TTM ) ₹164.81m Ricavi(TTM ) ₹14.49b
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) SEQUENT Conto economico (TTM ) Ricavi ₹14.49b Costo del fatturato ₹8.10b Profitto lordo ₹6.39b Altre spese ₹6.23b Guadagni ₹164.81m
Ultimi guadagni dichiarati
Sep 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.66 Margine lordo 44.10% Margine di profitto netto 1.14% Rapporto debito/patrimonio netto 60.9%
Come si è comportato SEQUENT nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2025/01/20 14:29 Prezzo dell'azione a fine giornata 2025/01/20 00:00 Guadagni 2024/09/30 Guadagni annuali 2024/03/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Sequent Scientific Limited è coperta da 2 analisti. 0 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Nikhil Shetty BP Wealth Management Private Limited null null IIFL Wealth Management Ltd.
Mostra 0 altri analisti 
